Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Christina Lake CannabisCLCFF +16.28% 3-Year EBITDA Growth Rate is 10.60% as of Feb. 2026, which is 5% above its 10-year median of 10.05. The stock has 4 warning signs investors should review. Among 813 Drug Manufacturers companies, Christina Lake Cannabis ranks better than 53.75% on this metric.
During the past 12 months, Christina Lake Cannabis's average EBITDA Per Share Growth Rate was -120.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 10.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Christina Lake Cannabis was 35.40% per year. The lowest was -98.80% per year. And the median was 10.05% per year.
Christina Lake Cannabis (OTCPK:CLCFF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Christina Lake Cannabis 3-Year EBITDA Growth Rate Related Terms
CLCFF vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Christina Lake Cannabis's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Christina Lake Cannabis 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Christina Lake Cannabis's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Christina Lake Cannabis's 3-Year EBITDA Growth Rate falls into.
Christina Lake Cannabis 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 10.60% mean?
Christina Lake Cannabis (CLCFF) has a 3-Year EBITDA Growth Rate of 10.60% as of Feb. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Christina Lake Cannabis and its competitors. This is near median its historical median of 10.05. According to the industry distribution chart, Christina Lake Cannabis ranks #376 out of 813 companies in the Drug Manufacturers industry, placing it in the top 46.2%.
Is Christina Lake Cannabis' 3-Year EBITDA Growth Rate too high?
Christina Lake Cannabis' current 3-Year EBITDA Growth Rate of 10.60% is near median its 10-year median of 10.05. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Christina Lake Cannabis' value of 10.60% is 19.1% above this industry median. Based on the distribution chart, Christina Lake Cannabis ranks #376 out of 813 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Christina Lake Cannabis' 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Christina Lake Cannabis ranks #376 out of 813 companies for 3-Year EBITDA Growth Rate. This puts Christina Lake Cannabis in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Christina Lake Cannabis' value of 10.60% is 19.1% above this benchmark. While the company's 10-year median is 10.05 vs. the industry median of 8.90, Christina Lake Cannabis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Christina Lake Cannabis's current 3-Year EBITDA Growth Rate of 10.60% is 19.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Christina Lake Cannabis and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Christina Lake Cannabis's current 3-Year EBITDA Growth Rate is 10.60%, which is near median its own 10-year median of 10.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Christina Lake Cannabis stock overvalued right now?
Based on GuruFocus' analysis, Christina Lake Cannabis (CLCFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.02 — trading 100% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 10.60%, which is near median its 10-year median of 10.05 and 19.1% above the Drug Manufacturers industry median of 8.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Christina Lake Cannabis (CLCFF), the current 3-Year EBITDA Growth Rate is 10.60% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Christina Lake Cannabis Corp is a licensed producer of cannabis. The company cultivates cannabis using strains specifically developed for outdoor cultivation. It is a producer of high-quality, low-cost, sun-grown cannabis flowers, oil cannabinoids, and hemp-based extracts and derivatives, serving domestic and international markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLCFF has been successfully added to your 
